| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/14/2013 | US8440641 Phthalocyanine salt formulations |
| 05/14/2013 | US8440640 Methods and compositions for treating obesity and related disorders |
| 05/14/2013 | US8440639 Combination compositions for reducing intraocular pressure |
| 05/14/2013 | US8440638 contacting islet cell with an agent that increases intracellular levels of 0-acetyl-ADP-ribose, resulting in cellular depolarization and/or Ca2+ entry which modulates insulin secretion; puromycin; agent which inhibits sirtuin activity thereby preventing islet cell death; nicotinamide |
| 05/14/2013 | US8440634 Bicyclic derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics |
| 05/14/2013 | US8440633 Anthelmintic combination |
| 05/14/2013 | US8440632 Protopanaxadiol-type ginsenoside compositions and uses thereof |
| 05/14/2013 | US8440631 Compositions for drug administration |
| 05/14/2013 | US8440630 Akt activity specifically inhibiting polypeptide |
| 05/14/2013 | US8440623 Polymer stabilized neuropeptides |
| 05/14/2013 | US8440619 Utilization of hypertension/hypercardia-preventing effect of D-allose |
| 05/14/2013 | US8440613 Controlling diseases caused by trichomonadida |
| 05/14/2013 | US8440612 Controlling giardiosis |
| 05/14/2013 | US8440591 Pesticidal composition comprising synthetic compound useful as nodulation agent of leguminous plants and a fungicide compound |
| 05/14/2013 | US8440402 Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy |
| 05/14/2013 | US8440232 Methods of treatment using a gastric retained gabapentin dosage |
| 05/14/2013 | US8440229 Hollow silica nanospheres and methods of making same |
| 05/14/2013 | US8440227 Biodegradable, non-toxic biological adhesive and methods for use in abdominal surgery |
| 05/14/2013 | US8440221 Transdermal drug delivery method and system |
| 05/14/2013 | US8440220 Sustained release of drug antagonist; analgesic reservoir, barrier layer |
| 05/14/2013 | US8440216 Sustained release intraocular implants and related methods |
| 05/14/2013 | US8440210 Stabilized pharmaceutical product |
| 05/14/2013 | US8440209 Adhesive for medical applications and means for haemostasis |
| 05/14/2013 | US8440194 Angiogenesis inhibitors; immunomodulators; side effect reduction |
| 05/14/2013 | US8440190 Antibody variants |
| 05/14/2013 | US8440176 Covalently grafted pharmaceutically active polymers |
| 05/14/2013 | US8440172 Stable soluble salts of phenylbenzimidazole sulfonic acid at PHS at or below 7.0 |
| 05/14/2013 | CA2734403C Nicotine-containing product |
| 05/14/2013 | CA2734402C Nicotine-containing granulate |
| 05/14/2013 | CA2731368C 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
| 05/14/2013 | CA2725649C Tetomilast polymorphs |
| 05/14/2013 | CA2692561C Method for producing solifenacin or salts thereof |
| 05/14/2013 | CA2682179C Allyl sulfide compounds, and compositions and methods using said compounds for repelling blood-feeding arthropods |
| 05/14/2013 | CA2674084C Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| 05/14/2013 | CA2672191C (1r,6s)-2-azabicyclo[4.3.0] nonane-8,8-diphosphonic acid and its use in treating or preventing bone disorders, for example, osteoporosis or paget's disease |
| 05/14/2013 | CA2655959C Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| 05/14/2013 | CA2641303C Na/k-atpase ligand |
| 05/14/2013 | CA2637024C Substituted imidazole derivatives, compositions, and methods of use as ptpase inhibitors |
| 05/14/2013 | CA2635310C Anthracenedione compounds |
| 05/14/2013 | CA2630849C Polymorphs and amorphous forms of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1h-pyrazole-3-carbonitrile |
| 05/14/2013 | CA2626273C Cefquinome compositions and methods of their use |
| 05/14/2013 | CA2612710C Diazo ligand platinum analogs |
| 05/14/2013 | CA2611889C Substituted tetrahydroquinolines |
| 05/14/2013 | CA2609972C Method and compositions for treatment of chronic neuropathic pain |
| 05/14/2013 | CA2605332C Method and composition for inhibiting cell proliferation and angiogenesis |
| 05/14/2013 | CA2602854C Compounds for the treatment of metabolic disorders |
| 05/14/2013 | CA2602210C Tablet-type controlled-release preparation containing cinnarizine and dimenhydrinate for combating vertigo |
| 05/14/2013 | CA2599502C Sublingual coated tablet |
| 05/14/2013 | CA2589237C (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4homopiperazine hydrochloride dihydrate |
| 05/14/2013 | CA2587266C Substituted pteridines for treating inflammatory diseases |
| 05/14/2013 | CA2583550C Thienopyridines as allosteric potentiators of the m4 muscarinic receptor |
| 05/14/2013 | CA2583333C Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 05/14/2013 | CA2580250C Loxapine analogs and methods of use thereof |
| 05/14/2013 | CA2579353C Therapeutic strategy for treating autoimmune and degenerative diseases |
| 05/14/2013 | CA2571519C Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant |
| 05/14/2013 | CA2568391C Coated tablet formulation and method |
| 05/14/2013 | CA2562287C Sustained-release oral molsidomine composition for treating atherosclerosis |
| 05/14/2013 | CA2560927C Insulin resistance-improving agent |
| 05/14/2013 | CA2557433C Quinazoline derivatives and therapeutic use thereof |
| 05/14/2013 | CA2556383C Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies |
| 05/14/2013 | CA2555463C Inhibitors of tgf-r signaling for treatment of cns disorders |
| 05/14/2013 | CA2552463C New compositions containing quinoline compounds |
| 05/14/2013 | CA2549114C Immunostimulant composition comprising at least one toll-like 7 receptor or toll-like 8 receptor agonist and a toll-like 4 receptor agonist |
| 05/14/2013 | CA2548202C Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo |
| 05/14/2013 | CA2547343C Analogs of benzoquinone-containing ansamycins for the treatment of cancer |
| 05/14/2013 | CA2546657C 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| 05/14/2013 | CA2539982C Pantoprazole multiparticulate formulations |
| 05/14/2013 | CA2535714C Phenoxyacetic acid derivatives |
| 05/14/2013 | CA2532965C 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| 05/14/2013 | CA2520521C Preserved ophthalmic compositions |
| 05/14/2013 | CA2516624C 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders |
| 05/14/2013 | CA2516399C Pharmaceutical compositions of safingol and methods of using the same |
| 05/14/2013 | CA2514720C Coated particles and pharmaceutical dosage forms |
| 05/14/2013 | CA2513496C Amino acid phenoxy ethers |
| 05/14/2013 | CA2509827C A set of oligo-nucleotides against hiv infection and its application in the prevention and treatment of acquired immune deficiency syndrome |
| 05/14/2013 | CA2497572C Akt inhibitors, pharmaceutical compositions, and uses thereof |
| 05/14/2013 | CA2465753C Orodispersible tablet having high homogeneity and the preparation method thereof |
| 05/14/2013 | CA2461916C Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis |
| 05/14/2013 | CA2460352C Composition and transdermal drug delivery device |
| 05/14/2013 | CA2455915C Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 05/14/2013 | CA2435562C Carotenoids as anti-hypertension agents |
| 05/14/2013 | CA2419469C Derivatives of peptides and peptide mimetics having integrin inhibitor properties ii |
| 05/14/2013 | CA2388298C The use of csf-1 inhibitors |
| 05/14/2013 | CA2362606C Therapeutic antimicrobial compositions |
| 05/14/2013 | CA2242342C Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 05/10/2013 | WO2013067537A1 Nanoparticle-based drug delivery |
| 05/10/2013 | WO2013067530A2 Virion derived protein nanoparticles for delivering radioisotopes for the diagnosis and treatment of malignant and systemic disease and the monitoring of therapy |
| 05/10/2013 | WO2013067485A1 Nutritional supplement for weight management |
| 05/10/2013 | WO2013067483A1 Delivery systems for improving oral bioavailability of fenobam, its hydrates, and salts |
| 05/10/2013 | WO2013067449A1 Pharmaceutical compositions of hydrophobic camptothecin derivatives |
| 05/10/2013 | WO2013067434A1 Pak inhibitors for the treatment of fragile x syndrome |
| 05/10/2013 | WO2013067425A1 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same |
| 05/10/2013 | WO2013067423A1 Pak inhibitors for the treatment of cell proliferative disorders |
| 05/10/2013 | WO2013067410A1 Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating cftr mediated diseases |
| 05/10/2013 | WO2013067409A1 Antimicrobial carboline compounds |
| 05/10/2013 | WO2013067396A2 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
| 05/10/2013 | WO2013067379A1 Pharmaceutical compositions comprising napthamides |
| 05/10/2013 | WO2013067346A1 Dermal delivery compositions and methods |
| 05/10/2013 | WO2013067308A2 Compositions and methods for inducing disruption of blood vasculature and for reducing angiogenesis |
| 05/10/2013 | WO2013067306A1 Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers |